Short description
Amryt Pharma creates and delivers innovative treatments to help patients with rare and orphan diseases live better lives.
Description
Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.
Amryt’s lead product, Episalvan, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan as a new treatment for a hereditary skin disorder called Epidermolysis Bullosa in both Europe and the U.S.
Amryt’s earlier-stage products are focussed on developing novel, next-generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there are high unmet medical needs. These include acromegaly and Cushing's disease.
Last funding
Noaccessforu
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Dublin, Dublin, Ireland, Europe
Founded on
January 1, 2012
Exited on
June 22, 2012
Went public on
June 22, 2012
Stock symbol
AMYT
Non-profit?
No
Acquired?
No
Employees count
251-500
Revenue range
$7890 - 12340
Sign in for full access
Investors
Cannot Access, No Way, Uh Ohhhh, Absolutely Noaccess, Blurry Noaccess, Cannot Access, Noway Youcantaccess
Sign in for full access
Founders
Cathal Friel, Joseph Wiley